Bayer/Regeneron's Eylea sees third eye indication in MYRROR
This article was originally published in Scrip
Regeneron Pharmaceuticals and Bayer's eye drug Eylea (aflibercept) has performed well in a Phase III trial in a new indication, myopic choroidal neovascularisation (mCNV), top-line data show. Bayer, which has marketing rights to the product outside the US, expects to make the first filing for the product in this indication by the end of the year in Asia, where this disease is particularly common.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.